SCHEMBL16557442

SCHEMBL16557442

Cc1cnc(Cl)c(NC(=O)CN(c2cc(C)ccc2C)S(=O)(=O)c2ccccc2)c1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.56
▸ SMN1; SMN2 Q16637 4/20 0.56
▸ POLB P06746 2/20 0.56
▸ TP53 P04637 3/20 0.54
▸ MAPT P10636 2/20 0.54
▸ THRB P10828 2/20 0.54
▸ ALDH1A1 P00352 1/20 0.54
▸ GAA P10253 1/20 0.53
▸ CYP3A4 P08684 1/20 0.51
▸ CYP2D6 P10635 1/20 0.51
▸ CYP2C9 P11712 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ NPSR1 Q6W5P4 1/20 0.51
▸ OXTR P30559 2/20 0.51
▸ AVPR1A P37288 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ ATM Q13315 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16557602 0.90 HPGD (0.59) TP53MAPTTHRBALDH1A1OXTR
SCHEMBL16557446 0.89 LMNA (0.59) LMNASMN1; SMN2POLBTP53MAPT
SCHEMBL16557452 0.85 LMNA (0.64) LMNASMN1; SMN2POLBTP53MAPT
SCHEMBL16557455 0.84 LMNA (0.67) LMNASMN1; SMN2POLBTP53MAPT
SCHEMBL16557440 0.83 LMNA (0.62) LMNASMN1; SMN2POLBTP53MAPT
SCHEMBL16557444 0.83 MAPT (0.61) LMNASMN1; SMN2POLBTP53MAPT
SCHEMBL16557441 0.82 SMN1; SMN2 (0.58) LMNASMN1; SMN2POLBTP53MAPT
SCHEMBL15583845 0.82 HPGD (0.70) POLBMAPTHPGD
SCHEMBL16557445 0.81 SMN1; SMN2 (0.62) LMNASMN1; SMN2POLBTP53MAPT
SCHEMBL16557432 0.81 MAPT (0.59) LMNASMN1; SMN2POLBTP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9790233-B2 Compositions and methods of modulating 15-PGDH activity CASE WESTERN RESERVE UNIVERSITY (US) 2017-10-17 — — US disclosed
US-20170165241-A1 COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2017-06-15 — — US disclosed
US-20150072998-A1 COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2015-03-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170165241-A1 COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY PTGS1, HPGD, PTGIS LMNA 1628/4885SMN1; SMN2 3855/4885POLB 1826/4885
US-20150072998-A1 COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY PTGS1, HPGD, PTGIS LMNA 1628/4885SMN1; SMN2 3855/4885POLB 1826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback